| Filed | Form | Description | |
|---|---|---|---|
| 4/8/25 | DEFA14A | DEFA14A | → |
| 4/8/25 | DEF 14A | DEF 14A | → |
| 3/28/25 | PRE 14A | PRE 14A | → |
| 4/16/24 | DEF 14A | DEF 14A | → |
| 4/19/23 | DEF 14A | DEF 14A | → |
| Filed | Form | Description | |
|---|---|---|---|
| 1/12/26 | 4 | PRIMARY DOCUMENT | → |
| 1/5/26 | 4 | PRIMARY DOCUMENT | → |
| 1/5/26 | 4 | PRIMARY DOCUMENT | → |
| 1/5/26 | 4 | PRIMARY DOCUMENT | → |
| 1/5/26 | 4 | PRIMARY DOCUMENT | → |
| 1/5/26 | 4 | PRIMARY DOCUMENT | → |
| ↓ | |||
MAIA Biotechnology, Inc. is a public, immune-oncology company based in Chicago, IL focused on the development of telomere targeting agents for the treatment of telomerase-positive cancer cells.